{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:46:15Z","timestamp":1793936775648,"version":"4.8.0"},"reference-count":158,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antifungal prophylaxis is the standard of care for patients undergoing intensive chemotherapy for haematological malignancy or haematopoietic cell transplantation (HCT). Prophylaxis with azoles reduces invasive fungal infections and may reduce mortality. However, breakthrough infections still occur, and the use of azoles is sometimes complicated by pharmacokinetic variability, drug interactions, adverse events and other issues. Echinocandins are highly active against Candida species, including some organisms resistant to azoles, and have some clinical activity against Aspergillus species as well. Although currently approved echinocandins require daily intravenous administration, the drugs have a favourable safety profile and more predictable pharmacokinetics than mould-active azoles. Clinical data support the efficacy and safety of echinocandins for antifungal prophylaxis in haematology and HCT patients, though data are less robust than for azoles. Notably, sparse evidence exists supporting the use of echinocandins as antifungal prophylaxis for patients with significant graft-versus-host disease (GvHD) after HCT. Two drugs that target (1,3)-\u03b2-d-glucan are in development, including an oral glucan synthase inhibitor and an echinocandin with unique pharmacokinetics permitting subcutaneous and weekly administration. Echinocandins are a reasonable alternative to azoles and other agents for antifungal prophylaxis in patients undergoing intensive chemotherapy for haematological malignancy or those receiving HCT, excluding those with significant GvHD.<\/jats:p>","DOI":"10.1093\/jac\/dkx450","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T20:13:12Z","timestamp":1510776792000},"page":"i60-i72","source":"Crossref","is-referenced-by-count":29,"title":["Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies"],"prefix":"10.1093","volume":"73","author":[{"given":"David J","family":"Epstein","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Stanford University, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K","family":"Seo","sequence":"first","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M","family":"Brown","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Stanford University, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A","family":"Papanicolaou","sequence":"first","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"2020042911260347600_dkx450-B1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface","volume":"44","author":"Tomblyn","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B2","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.clinthera.2011.01.009","article-title":"Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials","volume":"32","author":"Ziakas","year":"2010","journal-title":"Clin Ther"},{"key":"2020042911260347600_dkx450-B3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Fleming","year":"2014","journal-title":"Intern Med J"},{"key":"2020042911260347600_dkx450-B6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-014-2108-y","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"93","author":"Tacke","year":"2014","journal-title":"Ann Hematol"},{"key":"2020042911260347600_dkx450-B7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clinthera.2013.11.010","article-title":"Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis","volume":"36","author":"Ziakas","year":"2014","journal-title":"Clin Ther"},{"key":"2020042911260347600_dkx450-B8","volume-title":"Prevention and Treatment of Cancer-Related Infections Versions 2","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"2020042911260347600_dkx450-B9","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/cncr.10610","article-title":"Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials","volume":"94","author":"Bow","year":"2002","journal-title":"Cancer"},{"key":"2020042911260347600_dkx450-B10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/cid\/cit781","article-title":"Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia","volume":"58","author":"Fisher","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B11","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020042911260347600_dkx450-B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12464","article-title":"The role of primary antifungal prophylaxis in patients with haematological malignancies","volume":"20","author":"Pagano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020042911260347600_dkx450-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-006-0025-x","article-title":"Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients","volume":"162","author":"Bhatti","year":"2006","journal-title":"Mycopathologia"},{"key":"2020042911260347600_dkx450-B14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2010.256","article-title":"Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success","volume":"46","author":"Kontoyiannis","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B15","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/cir886","article-title":"Future directions in mucormycosis research","volume":"54","author":"Kontoyiannis","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000321504","article-title":"Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis","volume":"124","author":"Lewis","year":"2010","journal-title":"Acta Haematol"},{"key":"2020042911260347600_dkx450-B17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2009.08.015","article-title":"Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Amigues","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B19","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"2020042911260347600_dkx450-B20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MJT.0b013e3181ff7e10","article-title":"Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections","volume":"19","author":"Lewis","year":"2012","journal-title":"Am J Ther"},{"key":"2020042911260347600_dkx450-B21","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1093\/cid\/civ814","article-title":"Echinocandins: the expanding antifungal armamentarium","volume":"61","author":"Aguilar-Zapata","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/QCO.0b013e328358b000","article-title":"Risks for infection in patients with myelodysplasia and acute leukemia","volume":"25","author":"Pagano","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2020042911260347600_dkx450-B23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"2020042911260347600_dkx450-B24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/513764","article-title":"1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America","volume":"25","author":"Hughes","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020042911260347600_dkx450-B26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.transproceed.2012.07.149","article-title":"Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis","volume":"45","author":"Xu","year":"2013","journal-title":"Transplant Proc"},{"key":"2020042911260347600_dkx450-B27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3324\/haematol.2010.030825","article-title":"Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study","volume":"96","author":"Even","year":"2011","journal-title":"Haematologica"},{"key":"2020042911260347600_dkx450-B28","doi-asserted-by":"crossref","first-page":"e0128410.","DOI":"10.1371\/journal.pone.0128410","article-title":"High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS One"},{"key":"2020042911260347600_dkx450-B29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study","volume":"36","author":"De Castro","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1399-3062.2008.00321.x","article-title":"occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation","volume":"10","author":"Tomonari","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"2020042911260347600_dkx450-B31","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2014.02.018","article-title":"Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B34","doi-asserted-by":"crossref","first-page":"ofx050","DOI":"10.1093\/ofid\/ofx050","article-title":"Infections in hematopoietic cell transplant recipients: results from the organ transplant infection project, a multicenter, prospective, cohort study","volume":"4","author":"Schuster","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020042911260347600_dkx450-B35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24499","article-title":"Low incidence of Pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy","volume":"91","author":"Barreto","year":"2016","journal-title":"Am J Hematol"},{"key":"2020042911260347600_dkx450-B36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2020042911260347600_dkx450-B37","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"2020042911260347600_dkx450-B38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.21776","article-title":"Invasive fungal disease in patients treated for newly diagnosed acute leukemia","volume":"85","author":"Hammond","year":"2010","journal-title":"Am J Hematol"},{"key":"2020042911260347600_dkx450-B39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy","volume":"75","author":"Neofytos","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020042911260347600_dkx450-B40","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/jac\/dkv087","article-title":"The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality","volume":"70","author":"Wang","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020042911260347600_dkx450-B41","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"2020042911260347600_dkx450-B42","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/cncr.23466","article-title":"The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"2020042911260347600_dkx450-B43","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cncr.20554","article-title":"Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies","volume":"101","author":"Hachem","year":"2004","journal-title":"Cancer"},{"key":"2020042911260347600_dkx450-B44","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"2020042911260347600_dkx450-B45"},{"key":"2020042911260347600_dkx450-B46","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1200\/JCO.2008.21.0856","article-title":"Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve","volume":"27","author":"Portugal","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020042911260347600_dkx450-B47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0268-960X(95)90024-1","article-title":"Disorders of neutrophil function","volume":"9","author":"Bogomolski-Yahalom","year":"1995","journal-title":"Blood Rev"},{"key":"2020042911260347600_dkx450-B48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol"},{"key":"2020042911260347600_dkx450-B49","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cncr.28638","article-title":"Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: need for more resources","volume":"120","author":"Cogle","year":"2014","journal-title":"Cancer"},{"key":"2020042911260347600_dkx450-B50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474086.2016.1181540","article-title":"The risk of infections in patients with myelodysplastic syndromes in 2016","volume":"9","author":"Caira","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"2020042911260347600_dkx450-B51","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2020042911260347600_dkx450-B52","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020042911260347600_dkx450-B53","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"2020042911260347600_dkx450-B54","author":"Sehn"},{"key":"2020042911260347600_dkx450-B55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/10428194.2016.1204652","article-title":"Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study","volume":"58","author":"Mariette","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2020042911260347600_dkx450-B56","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2020042911260347600_dkx450-B57","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2009.03.006","article-title":"Infections in patients with multiple myeloma","volume":"46","author":"Nucci","year":"2009","journal-title":"Semin Hematol"},{"key":"2020042911260347600_dkx450-B58","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bmt.2016.18","article-title":"Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey","volume":"51","author":"Niederwieser","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B59","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2016.156356","article-title":"Improved survival after acute graft-versus-host disease diagnosis in the modern era","volume":"102","author":"Khoury","year":"2017","journal-title":"Haematologica"},{"key":"2020042911260347600_dkx450-B60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0609.2004.00273.x","article-title":"Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients","volume":"73","author":"Jantunen","year":"2004","journal-title":"Eur J Haematol"},{"key":"2020042911260347600_dkx450-B61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00277-002-0484-1","article-title":"Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma","volume":"81","author":"Auner","year":"2002","journal-title":"Ann Hematol"},{"key":"2020042911260347600_dkx450-B62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1365-2141.2000.02202.x","article-title":"Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue","volume":"110","author":"Wardley","year":"2000","journal-title":"Br J Haematol"},{"key":"2020042911260347600_dkx450-B63","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.187","article-title":"Comparison of infectious complications during induction\/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation","volume":"45","author":"Orasch","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B64","doi-asserted-by":"crossref","first-page":"584.","DOI":"10.1186\/s12879-015-1329-6","article-title":"Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study","volume":"15","author":"Harrison","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2020042911260347600_dkx450-B65","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B66","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbmt.2015.09.014","article-title":"The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review","volume":"22","author":"Chaudhry","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B67","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/blood-2006-04-020172","article-title":"Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen","volume":"109","author":"Takahashi","year":"2007","journal-title":"Blood"},{"key":"2020042911260347600_dkx450-B68","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-011-1299-8","article-title":"Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials","volume":"91","author":"Chang","year":"2012","journal-title":"Ann Hematol"},{"key":"2020042911260347600_dkx450-B69","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","article-title":"Glucocorticosteroid therapy: mechanisms of action and clinical considerations","volume":"84","author":"Fauci","year":"1976","journal-title":"Ann Intern Med"},{"key":"2020042911260347600_dkx450-B70","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"key":"2020042911260347600_dkx450-B71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bmt.2009.39","article-title":"Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients","volume":"44","author":"Mikulska","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B72","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","article-title":"Higher risk of cytomegalovirus and Aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease","volume":"13","author":"van Burik","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/bmt.2015.316","article-title":"The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis","volume":"51","author":"Williams","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B74","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000334113","article-title":"The increased risk for Pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim\/sulfamethoxazole: a single-center experience","volume":"127","author":"Hardak","year":"2012","journal-title":"Acta Haematol"},{"key":"2020042911260347600_dkx450-B75","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.2820360912","article-title":"Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis","volume":"36","author":"Hughes","year":"1975","journal-title":"Cancer"},{"key":"2020042911260347600_dkx450-B76","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bbmt.2016.06.008","article-title":"Risk factors for invasive mold infections and implications for choice of prophylaxis after allogeneic stem cell transplantation","volume":"22","author":"Blennow","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","article-title":"Biology and clinical application of CAR T cells for B cell malignancies","volume":"104","author":"Davila","year":"2016","journal-title":"Int J Hematol"},{"key":"2020042911260347600_dkx450-B78","doi-asserted-by":"crossref","first-page":"89.","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"2020042911260347600_dkx450-B79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11899-017-0381-2","article-title":"The future of targeting FLT3 activation in AML","volume":"12","author":"Leick","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"2020042911260347600_dkx450-B80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia\u2014major progress over four decades and glimpses into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"key":"2020042911260347600_dkx450-B81","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","article-title":"New therapeutic strategies in acute lymphocytic leukemia","volume":"12","author":"Man","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"2020042911260347600_dkx450-B82","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S1470-2045(14)70459-0","article-title":"Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye\u2014Authors' reply","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"2020042911260347600_dkx450-B83","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1093\/cid\/civ817","article-title":"Intermittent dosing of micafungin is effective for treatment of experimental disseminated candidiasis in persistently neutropenic rabbits","volume":"61","author":"Petraitiene","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B84","year":"2014"},{"key":"2020042911260347600_dkx450-B85","year":"2015"},{"key":"2020042911260347600_dkx450-B86","year":"2016"},{"key":"2020042911260347600_dkx450-B87","year":"2014"},{"key":"2020042911260347600_dkx450-B88","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"2020042911260347600_dkx450-B89","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B90","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"2020042911260347600_dkx450-B91","author":"Sengar"},{"key":"2020042911260347600_dkx450-B92","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/jac\/dkr271","article-title":"A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)","volume":"66","author":"Cattaneo","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020042911260347600_dkx450-B93","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cam4.225","article-title":"Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study","volume":"3","author":"Kung","year":"2014","journal-title":"Cancer Med"},{"key":"2020042911260347600_dkx450-B94","author":"Deslandes"},{"key":"2020042911260347600_dkx450-B95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2020042911260347600_dkx450-B96","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11908-011-0220-x","article-title":"Long-term voriconazole and skin cancer: is there cause for concern?","volume":"13","author":"Clancy","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"2020042911260347600_dkx450-B97","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/ijh.15.7","article-title":"Role of antimicrobial prophylaxis during treatment of adults with acute leukemia","volume":"4","author":"Cohen","year":"2015","journal-title":"Int J Hematol Oncol"},{"key":"2020042911260347600_dkx450-B98","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkx133","article-title":"Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020042911260347600_dkx450-B99","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020042911260347600_dkx450-B100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01290-16","article-title":"High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of Pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy","volume":"61","author":"Ponce","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B101","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00204-016-1916-3","article-title":"New developments and directions in the clinical application of the echinocandins","volume":"91","author":"Chang","year":"2017","journal-title":"Arch Toxicol"},{"key":"2020042911260347600_dkx450-B102","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/INF.0b013e31821b95e2","article-title":"Echinocandins in children","volume":"30","author":"Hoffman","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2020042911260347600_dkx450-B103","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"2020042911260347600_dkx450-B104","doi-asserted-by":"crossref","first-page":"e8524.","DOI":"10.1371\/journal.pone.0008524","article-title":"Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection","volume":"5","author":"Cushion","year":"2010","journal-title":"PLoS One"},{"key":"2020042911260347600_dkx450-B105","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1128\/IAI.01181-12","article-title":"Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of Pneumocystis pneumonia","volume":"81","author":"Linke","year":"2013","journal-title":"Infect Immun"},{"key":"2020042911260347600_dkx450-B106","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1128\/AAC.38.7.1480","article-title":"Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-\u03b2-d-glucan synthase","volume":"38","author":"Kurtz","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B107","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/589304","article-title":"Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal \u03b2-glucan exposure","volume":"198","author":"Hohl","year":"2008","journal-title":"J Infect Dis"},{"key":"2020042911260347600_dkx450-B108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AAC.00699-07","article-title":"Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia","volume":"52","author":"Antachopoulos","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B109","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2020042911260347600_dkx450-B110","doi-asserted-by":"crossref","first-page":"e70619.","DOI":"10.1371\/journal.pone.0070619","article-title":"Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice","volume":"8","author":"Lobo","year":"2013","journal-title":"PLoS One"},{"key":"2020042911260347600_dkx450-B111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: a comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"2020042911260347600_dkx450-B112","year":"2017"},{"key":"2020042911260347600_dkx450-B113","year":"2006"},{"key":"2020042911260347600_dkx450-B114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2007.09.018","article-title":"Population pharmacokinetics of micafungin in adult patients","volume":"60","author":"Gumbo","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020042911260347600_dkx450-B115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijantimicag.2016.02.004","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations","volume":"47","author":"Yang","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2020042911260347600_dkx450-B116","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B117","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/AAC.46.12.3846-3853.2002","article-title":"In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies","volume":"46","author":"Ernst","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B118","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-007-0411-4","article-title":"Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis","volume":"27","author":"Fleischhacker","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020042911260347600_dkx450-B119","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/AAC.45.2.596-600.2001","article-title":"Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/AAC.01337-06","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B121","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1093\/cid\/civ818","article-title":"Safety and efficacy of intermittent intravenous administration of high-dose micafungin","volume":"61","author":"Neofytos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B122","doi-asserted-by":"crossref","first-page":"S669","DOI":"10.1093\/cid\/civ725","article-title":"Potential microbiological effects of higher dosing of echinocandins","volume":"61","author":"Steinbach","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B123","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14740338.2017.1273900","article-title":"An update on the safety and interactions of antifungal drugs in stem cell transplant recipients","volume":"16","author":"Girmenia","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2020042911260347600_dkx450-B124","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2710.2011.01309.x","article-title":"Flash pulmonary oedema during anidulafungin administration","volume":"37","author":"Hindahl","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2020042911260347600_dkx450-B125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jcpt.12078","article-title":"Cardiac effects of echinocandin preparations - three case reports","volume":"38","author":"Lichtenstern","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2020042911260347600_dkx450-B126","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jcpt.12046","article-title":"A severe case of haemodynamic instability during anidulafungin administration","volume":"38","author":"Fink","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2020042911260347600_dkx450-B127","doi-asserted-by":"crossref","first-page":"S662","DOI":"10.1093\/cid\/civ739","article-title":"Antifungal-associated drug-induced cardiac disease","volume":"61","author":"Cleary","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12831","article-title":"Mechanisms of echinocandin antifungal drug resistance","volume":"1354","author":"Perlin","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"2020042911260347600_dkx450-B129","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B130","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3201\/eid2011.140685","article-title":"Drug-resistant Candida glabrata infection in cancer patients","volume":"20","author":"Farmakiotis","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2020042911260347600_dkx450-B131","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020042911260347600_dkx450-B132","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-007-0011-1","article-title":"Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation","volume":"87","author":"Hashino","year":"2008","journal-title":"Int J Hematol"},{"key":"2020042911260347600_dkx450-B133","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-008-0196-y","article-title":"Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation","volume":"88","author":"Hiramatsu","year":"2008","journal-title":"Int J Hematol"},{"key":"2020042911260347600_dkx450-B134","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jinf.2016.06.011","article-title":"Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients","volume":"73","author":"Park","year":"2016","journal-title":"J Infect"},{"key":"2020042911260347600_dkx450-B135","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","article-title":"Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant","volume":"18","author":"Huang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B136","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ejh.12368","article-title":"Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the Cologne Cohort for Neutropenic Patients","volume":"93","author":"Vehreschild","year":"2014","journal-title":"Eur J Haematol"},{"key":"2020042911260347600_dkx450-B137","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B138","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.01527-13","article-title":"Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia","volume":"58","author":"Gomes","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B139","author":"Huang"},{"key":"2020042911260347600_dkx450-B140","doi-asserted-by":"crossref","first-page":"e0180050.","DOI":"10.1371\/journal.pone.0180050","article-title":"Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: a meta-analysis of randomized controlled trials","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"2020042911260347600_dkx450-B141","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.01057-13","article-title":"Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization","volume":"57","author":"Andes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B142","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.bbmt.2010.05.002","article-title":"Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"16","author":"Mehta","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042911260347600_dkx450-B143","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10156-007-0522-Y","article-title":"Relationship between the initial dose of micafungin and its efficacy in patients with candidemia","volume":"13","author":"Ota","year":"2007","journal-title":"J Infect Chemother"},{"key":"2020042911260347600_dkx450-B144","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2020042911260347600_dkx450-B145","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B146","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B147","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B148","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020042911260347600_dkx450-B149","author":"ClinicalTrials.gov"},{"key":"2020042911260347600_dkx450-B150","doi-asserted-by":"crossref","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B151","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"2020042911260347600_dkx450-B152","doi-asserted-by":"crossref","first-page":"e02045","DOI":"10.1128\/AAC.02045-16","article-title":"Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042911260347600_dkx450-B153","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020042911260347600_dkx450-B154","author":"Ong"},{"key":"2020042911260347600_dkx450-B155","author":"Ong"},{"key":"2020042911260347600_dkx450-B156","author":"Cushion"},{"key":"2020042911260347600_dkx450-B157","author":"STRIVE"},{"key":"2020042911260347600_dkx450-B158","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ejh.12426","article-title":"Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study","volume":"94","author":"Nachbaur","year":"2015","journal-title":"Eur J Haematol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/suppl_1\/i60\/33143822\/dkx450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/suppl_1\/i60\/33143822\/dkx450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T15:28:27Z","timestamp":1588174107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/suppl_1\/i60\/4769709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":158,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2018,1,3]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx450","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}